

CHANGE OF STATUS REPORT

National Instrument 51-102 - *Continuous Disclosure Obligations*

To: British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission
Toronto Stock Exchange

RE: Medicenna Therapeutics Corp. (the “Corporation”)

Effective August 2, 2017, the Corporation’s common shares ceased trading on the TSX Venture Exchange and became listed on the Toronto Stock Exchange. As a result, the Corporation ceased to be a “venture issuer” (as such term is defined under National Instrument 51-102 - *Continuous Disclosure Obligations*) on August 2, 2017.

Dated this 2nd day of August, 2017.

MEDICENNA THERAPEUTICS CORP.

Per: “Elizabeth Williams”
Name: Elizabeth Williams
Title: CFO and Corporate Secretary